Identifying changes in DNA copy number can pinpoint genes that may be involved in tumor development. Here we have defined the smallest overlapping regions of imbalance (SORI) in testicular germ cell tumors other than the 12p region, which has been previously investigated. Definition of the regions was achieved through comparative genomic hybridization (CGH) analysis of a 4559 cDNA clone microarray. A total of 14 SORI were identified, which involved at least five of the 11 samples analysed. Many of these refined regions were previously reported using chromosomal or allelic imbalance studies. The SORI included gain of material from the regions 4q12, 17q21.3, 22q11.23 and Xq22, and loss from 5q33, 11q12.1, 16q22.3 and 22q11. Comparison with parallel chromosomal CGH data supported involvement of most regions. The various SORI span between one and 20 genes and highlight potential oncogenes/tumor suppressor genes to be investigated further (Supplementary material is available at http://www.crukdmf.icr.ac.uk/array/array.html). Oncogene (2004 Oncogene ( ) 23, 9142-9147. doi:10.1038 
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Keywords: TGCT; microarray CGH; regions of imbalance Testicular germ cell tumors of adolescents and young adults (TGCTs) are the most common malignancy in young Caucasian men. Despite the generally favorable outcome for TGCT treated with surgery, irradiation and cisplatin-based chemotherapy, it is still the leading cause of cancer deaths in this age group (Bosl and Motzer, 1997) . TGCTs are classified into the two main histological categories of seminomas and nonseminomas. Seminomas resemble primordial germ cells whereas nonseminomas are composed of neoplastic tissues exhibiting either somatic, embryonal or extraembryonal tissues (Mostofi, 1973) .
All TGCTs show gain of the short arm of chromosome 12 (Rodriguez et al., 2003; Zafarana et al., 2003) . Analysis of TGCT with amplification of the 12p11.2-12.1 subregion has previously defined the minimum region of gain and suggested a number of genes that may be involved in the development of TGCTs (Rodriguez et al., 2003; Zafarana et al., 2003) . Cytogenetic, chromosome comparative genomic hybridization (CGH) and allelic imbalance studies have shown that a number of other regions of the genome are also imbalanced, although at a lower frequency than the gain of 12p material. Reported aberrations common to both tumor subtypes include gain of material from chromosomes 1, 7, 8, 17, 21 and X and loss of material from chromosomes 4, 5, 11, 13, 18 and Y (Korn et al., 1996; Mostert et al., 1996; Sandberg et al., 1996; van Echten et al., 1995; Summersgill et al., 2001; Kraggerud et al., 2002) . The consistency of these changes suggests that genes from these regions may be important in TGCT development. Here, we have sought to define regions of frequent chromosomal imbalance in the TGCT genome other than those at 12p, which we have previously reported (Rodriguez et al., 2003) . This has been achieved using CGH to cDNA microarrays, which is a powerful approach that can directly identify genes that are relatively gained or lost (Pollack et al., 1999; Clark et al., 2002; Rodriguez et al., 2003) . This has allowed characterization of the smallest overlapping regions of imbalance (SORI) at the resolution of individual genes.
The samples in Table 1 were analysed by cDNA microarray CGH and also by chromosomal CGH. The genomic distances spanning a region of imbalance extended to the nearest flanking unaltered gene on the array were determined for each sample. The data for each region in all samples were then compared and the SORI defined as the minimum overlapping region involved. The SORI involving at least five of the 11 samples analysed are shown in Table 2 with examples from analysis of individual cases shown in Figure 1 . Supplementary data are presented at http:// www.crukdmf.icr.ac.uk/array/array.html. The average ratios for clones plotted against chromosomal location are similar to the chromosomal CGH in many instances (Figure1 and Table 2 ). However, regions of imbalance involving a small number of genes maybe below the resolution of metaphase CGH (e.g. Figure 1g , h). The resolution of the cDNA array is limited by the number and distribution of the clones. In this study, the coverage was approximately 1 gene every 700 kb, although the distribution of these was variable throughout the genome. The low coverage in some regions may explain the finding that some regions were only detected by chromosomal CGH in some samples. High-level genomic gains or losses were detected in some samples. These regions overlapped with lower level copy number changes defined in other samples (see Table 2 ). Detection of copy number change will be influenced by a number of factors including tumor heterogeneity and contamination with infiltrating lymphocytes. Samples from RH24 and RH30 in particular were known to have high levels of normal cell contamination (Table 1 ) and tend to show lower levels of copy number imbalance. Chromosomal CGH may also be more sensitive because the ratios used to define a significant change are lower than those used in microarray analysis. The detection of copy number changes is validated here in sex mismatch experiments and through control experiments falsepositive clones were excluded from the subsequent analyses. False negatives could not be excluded in this way, although the overlap in the regions of imbalances identified between samples indicated that clones were responding appropriately.
The SORI defined here greatly refine many regions that have previously been shown to be frequently associated with TGCTs. In addition, small regions such as those defined at 4q12, 14q13.2, 16p13, 16q22.3, 22q11.23 and in one sample at 5q11 (Figure 1g , h) (http://www.crukdmf.icr.ac.uk/array/array.html) represent new minimal regions of imbalance. The smallest region defined was at 4q12 where three out of the 11 samples showed significant gain of the KIT gene only and not PDGFRA and KDR that are the nearest known flanking genes. Three additional samples showed gain that included all three of these genes. There was also a tendency towards loss of the chromosomal region more distal to this, consistent with previous chromosomal CGH analyses (Summersgill et al., 2001; Kraggerud et al., 2002) . The KIT gene encodes a tyrosine kinase transmembrane receptor and its high expression is well documented in seminomas (Izquierdo et al., 1995; Bokemeyer et al., 1996) . This is the first report of specific gain/amplification of this gene. Reports of activating mutations of KIT range in frequency from 1% of TGCTs to as high as 25% and a high frequency of KIT mutations have been identified in bilateral TGCT Kemmer et al., 2004; Rapley et al., 2004) . Taken together, these data suggest that activation of KIT plays a role in the development of at least some TGCT.
Chromosomes 7 and 8 have been reported as frequently gained in TGCTs (Mostert et al., 1996; Sandberg et al., 1996; Looijenga et al., 2000; Kraggerud et al., 2002) . We have previously defined an overlapping cytogenetic region of gain at 7pter-p22 and 8q21-q22 (Summersgill et al., 2001) . The current data are consistent with this and further refines the regions to within the 7p22 and 8q21 bands.
Recurrent gain of 17q has been observed in cultured human embryonic stem cells and is also found in TGCTs suggesting that dosage of this region provides a selective growth advantage (Korn et al., 1996; Looijenga et al., 2000; Summersgill et al., 2001; Draper et al., 2004) . Here a minimum region of overlapping gain has been defined at 17q21.3. The CDK5RAP3 gene at this location has been implicated in mediation of cellular proliferation in a cell line model (Chen et al., 2002) and therefore represents a candidate gene for involvement in TGCTs. Chromosome X is frequently gained in TGCTs and Klinefelters syndrome patients, who are associated with trisomy X, are at increased risk of developing extragonadal germ cell tumors. Therefore, it is particularly interesting that gain of a region at Xq22 was defined in seven samples. This region is, however, distinct from the TGCT predisposition locus suggested at Xq27 (Rapley et al., 2003) .
We define a SORI at 3q29, which is consistent with previous CGH and allelic imbalance studies that have indicated loss of 3q including one study that defined loss of 3q27-ter in 79% of samples (Looijenga et al., 2000; Skotheim et al., 2001b) . PAK2 lies within the region of genomic loss at 3q29 and is involved in apoptosis (Jakobi et al., 2003) . PAK2 also negatively controls the MYC proteins directly inhibiting their ability to activate transcription, sustain proliferation and transform NIH 3T3 cells in culture (Huang et al., 2004) . Loss of PAK2 combined with an increase in MYC gene products may have a synergistic effect and elevated expression of N-MYC and increased C-MYC protein levels have been documented in TGCTs (Watson et al., 1986; Shuin et Regions of imbalance identified in five or more of the 11 samples.The shading denotes samples in which genomic imbalances were found by CGH microarray to cDNA clones. Darker shading in (a) denotes regions that were determined to have again greater than or equal to six copies. In (b) this denotes samples with a loss determined to be greater or equal to three copies. Lighter shading denotes regions where an imbalance of
Regions of imbalance identified in five or more of the 11 samples. The shading denotes samples in which genomic imbalances were found by CGH microarray to cDNA clones. Darker shading in (a) denotes regions that were determined to have a gain greater than or equal to six copies. In (b) this denotes samples with a loss determined to be greater or equal to three copies. Lighter shading denotes regions where an imbalance of two copies was indicated. The written cytogenetic loci denote the regions identified by metaphase CGH analysis
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Genomic losses defined here, at 5q33 and 11q21.1, are supported by previous metaphase studies (Ottesen et al., 1997; Skotheim et al., 2001a) . In addition, three of the aberrations found in this study, loss at 9p13, 14q13.2 and gain at 16p13, are novel. These may not have been previously detected due to the small size of the regions and the lower resolution of metaphase CGH compared to cDNA microarray analyses.
The loss at 22q12 is centered around Chk2. Chk2 is a known tumor suppressor gene, which has been previously shown by immunochemical analysis to have decreased expression in subsets of TGCTs compared to Figure 1 Examples of array and Metaphase CGH Data. Genomic DNA was prepared from the primary samples indicated in Table 1 using established methods (Sambrook and Russell, 2001) . Chromosomal CGH was carried out and analysed as previously described (Lu et al., 1999; Summersgill et al., 2001) . The metaphase CGH profiles show the average CGH profile for the representative cases with the regions of imbalance indicated where the profile lies outside the normal:normal variation empirically determined in control experiments (black vertical line equals a ratio of 1 and the parallel gray lines are the cutoff ratios of 0.25 greater and less than this). Regions to the right and left of the chromosome ideogram show the regions of gain and loss, respectively. Centromeric regions may produce unreliable ratios. The microarray used to define regions of genomic imbalance consisted of 4559 non-12p cDNA clones from the Institute of Cancer Research and Cancer Research UK Geneset (www.crukdmf.icr.ac.uk/array/5808.pdf). Positional information is based on the July 2003 freeze of the Homo sapiens genome assembly available at the human genome browser website (http://www.genome.ucsc.edu). Hybridization and analysis of slides was as previously described (Clark et al., 2002; Rodriguez et al., 2003) . The data analyses included a number of steps to maximize sensitivity and retain robustness. The Cy5/Cy3 Log2 ratio data were adjusted to allow for signal intensity artifacts as in Clark et al. (2002) . Each clone was normalized according to its position on the array to adjust for regional variations in relative signal intensity on the slides. The data set was renormalized to a Log2 ratio of 0. Four separate normal male versus female hybridizations were also performed and data were normalized as described above. Autosomal cDNAs that showed a biased change outside 2 standard deviations of clones for chromosome 2 in individual experiments were excluded from any subsequent analyses. These control hybridizations were also used to determine the sensitivity of the system. Using the normal male versus normal female hybridizations a two fold change in X chromosome data was detectable and was found to be equivalent to 3 times the standard deviation of the autosomal data. These calculations were extended to the TGCT CGH microarray data and the standard deviation was calculated using chromosome 2 for each sample as an internal control. This chromosome infrequently shows copy number changes in TGCTs. Any changes in chromosome 2 would result in an underestimation of sensitivity and therefore aberrations identified would actually be of greater change than determined in such samples. As these tumors are generally triploid a change denoted by 3 standard deviations indicates an increase from three to six copies. From this data changes corresponding to an increase or decrease equal to a two fold change and, through extrapolation, to a four fold change were determined and are shown as the two black vertical lines on either side of the vertical line indicating the log2 ratio at 0. a, c, e, g, i and k show metaphase CGH individual chromosome profiles. b, d, f, h, j and l show cDNA microarray CGH individual chromosome profiles Defining minimum genomic regions A McIntyre et al human cultured cells and testicular tissues (Bartkova et al., 2001 ). This region is distinct from that identified as gained at 22q11.23 (Figure 1i and j) . Macrophage migration inhibitory factor (MIF) (22q11.23) has been linked to control of cell survival, angiogenesis, proliferation and tumor progression (Mitchell and Bucala, 2000) . Increased expression of MIF has been found in other tumor types including prostate and subpopulations of cells in progressive breast cancer where expression correlated with tumor growth (Karan et al., 2002; Reome et al., 2004) . MIF has been implicated in upregulation of N-MYC expression through MAPKdependant signalling (Ren et al., 2004) .
Some of the SORI defined here contain strong candidate genes already suggested to be involved in the development of TGCT while others contain genes of potential significance in TGCT. Further work to implicate the products of candidate genes from these regions in the development of TGCT is warranted and may lead to novel, less toxic approaches to treatment of these tumors.
